These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
70. Toll-like receptor expression in the blood and brain of patients and a mouse model of Parkinson's disease. Drouin-Ouellet J; St-Amour I; Saint-Pierre M; Lamontagne-Proulx J; Kriz J; Barker RA; Cicchetti F Int J Neuropsychopharmacol; 2014 Dec; 18(6):. PubMed ID: 25522431 [TBL] [Abstract][Full Text] [Related]
71. Selective expression of α-synuclein-immunoreactivity in vesicular acetylcholine transporter-immunoreactive axons in the guinea pig rectum and human colon. Sharrad DF; de Vries E; Brookes SJ J Comp Neurol; 2013 Feb; 521(3):657-76. PubMed ID: 22821666 [TBL] [Abstract][Full Text] [Related]
73. Parkinson's vaccine on trial. Pilcher H Lancet Neurol; 2005 Aug; 4(8):458-9. PubMed ID: 16086492 [No Abstract] [Full Text] [Related]
74. α-Synuclein and tau concentrations in cerebrospinal fluid of patients presenting with parkinsonism: a cohort study. Mollenhauer B; Locascio JJ; Schulz-Schaeffer W; Sixel-Döring F; Trenkwalder C; Schlossmacher MG Lancet Neurol; 2011 Mar; 10(3):230-40. PubMed ID: 21317042 [TBL] [Abstract][Full Text] [Related]
75. α-Synuclein vaccination modulates regulatory T cell activation and microglia in the absence of brain pathology. Christiansen JR; Olesen MN; Otzen DE; Romero-Ramos M; Sanchez-Guajardo V J Neuroinflammation; 2016 Apr; 13(1):74. PubMed ID: 27055651 [TBL] [Abstract][Full Text] [Related]
76. Parkinson's disease and alpha synuclein: is Parkinson's disease a prion-like disorder? Olanow CW; Brundin P Mov Disord; 2013 Jan; 28(1):31-40. PubMed ID: 23390095 [TBL] [Abstract][Full Text] [Related]
77. Monoclonal Antibodies in Neurodegenerative Disease May Work, But They Don't Help: A Perspective from Physicians. Richard E; Bloem BR J Parkinsons Dis; 2022; 12(8):2289-2291. PubMed ID: 36442210 [No Abstract] [Full Text] [Related]
78. Targeting α-Synuclein: A Further Viewpoint. Lang AE Mov Disord; 2023 Apr; 38(4):715-716. PubMed ID: 37061882 [No Abstract] [Full Text] [Related]
79. Monoclonal Antibody Therapy in Parkinson's Disease - The End? Whone A N Engl J Med; 2022 Aug; 387(5):466-467. PubMed ID: 35921458 [No Abstract] [Full Text] [Related]
80. This is NOT the End for Immunotherapy in Parkinson's Disease - A Perspective from Early Drug Development Scientists. Brundin P; Svoboda H; Bonni A; Pagano G J Parkinsons Dis; 2022; 12(8):2293-2296. PubMed ID: 36404558 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]